Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828359 | 0.87 | KMT2A (0.46) | PTGS1PTGS2KMT2AALDH1A1POLB | |
| SCHEMBL2834595 | 0.86 | PTGS1 (0.44) | PTGS1PTGS2KMT2AMEN1CYP2D6 | |
| SCHEMBL1826817 | 0.85 | L3MBTL1 (0.40) | PTGS1PTGS2KMT2AALDH1A1 | |
| SCHEMBL1824283 | 0.85 | L3MBTL1 (0.40) | PTGS1PTGS2KMT2AALDH1A1 | |
| SCHEMBL2832592 | 0.85 | PTGS1 (0.65) | PTGS1PTGS2KMT2AMEN1CYP2D6 | |
| SCHEMBL1825924 | 0.85 | PTGS1 (0.53) | PTGS1PTGS2KMT2AMEN1CYP2D6 | |
| SCHEMBL1826138 | 0.85 | PTGS1 (0.43) | PTGS1PTGS2KMT2AMEN1CYP2D6 | |
| SCHEMBL1820336 | 0.85 | PTGS1 (0.53) | PTGS1PTGS2KMT2AMEN1CYP2D6 | |
| SCHEMBL1826077 | 0.84 | PTGS1 (0.48) | PTGS1KMT2AMEN1CYP2D6ALDH1A1 | |
| SCHEMBL2839041 | 0.83 | PTGS1 (0.56) | PTGS1PTGS2KMT2AMEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714157-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20070270603-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-11-22 | — | — | US | disclosed |
| US-7271280-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-18 | — | — | US | disclosed |
| US-20040158093-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158093-A1 | Process for preparing a biaryl compound | CYP1B1, REL, CYP2F1 | PTGS1 3787/4885PTGS2 3426/4885KMT2A 1068/4885 |
| US-20070270603-A1 | Process for preparing a biaryl compound | CYP4A11, CYP4B1, CYP51A1 | PTGS1 3968/4885PTGS2 3168/4885KMT2A 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.